Region: United States of America

Patent litigation finance skyrockets in past three years

We compiled data from Westfleet Advisors’ annual litigation funding reports to find patent finance shot up by nearly 50% since 2020  – to the benefit of rights holders

10 March 2023

Federal Circuit fails to clear up REMS patent uncertainties in latest Orange Book ruling

Questions over FDA patent listing remain following Jazz v Avadel dispute

09 March 2023

A roadmap for industry-academia collaboration to advance IP policy

Ethical and transparent partnerships can help resolve pressing issues all while furthering a company’s goals and interests

08 March 2023

US commenters warn of ‘unintended consequences’ in pharma patent crackdown

Potential initiatives to limit continuation practice are causing deep divides in the life sciences patent community – causing technology licensors and Big Tech to take sides

07 March 2023

Infamous Cabilly patents come back to haunt Biogen in new Genentech suit

Highly-litigated intellectual property to feature in yet another dispute

07 March 2023

Five things to know about patent case trends in the Western District of Texas

Docket Navigator data shows more patentees are filing directly in Austin – possibly to sidestep the Waco Division’s random assignment order

06 March 2023

Nanoco eyeing further assertions following big-money Samsung pay-out, says CEO

Brian Tenner sits down with IAM to discuss the company’s win and future strategy

06 March 2023

Square peg in a round hole: the dangers of expanding the TRIPS waiver

Saturday Opinion: Disseminating covid diagnostics and therapeutics is critical, but attempting to do so via the TRIPS waiver extension is rife with unintended consequences

04 March 2023

Can ChatGPT replace a patent lawyer?

We asked the large-language model to draft a patent claim, design around a claim, and identify prior art – and concluded that it is potentially helpful but unreliable

02 March 2023

Public criticisms of pharma patents are “way overstated”, Kathi Vidal tells IAM

The USPTO director shares her thoughts on life sciences IP rights and ongoing collaboration with the FDA

02 March 2023

Unlock unlimited access to all IAM content